Live Breaking News & Updates on Alnylam Pharmaceuticals Stock
Stay updated with breaking news from Alnylam pharmaceuticals stock. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Swiss National Bank cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 2.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 390,800 shares of the biopharmaceutical company’s stock after selling 9,800 shares during the period. Swiss […] ....
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.75) by $0.23, Briefing.com reports. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. During the same […] ....
StockNews.com upgraded shares of Alnylam Pharmaceuticals (NASDAQ:ALNY – Free Report) from a hold rating to a buy rating in a report issued on Monday morning. A number of other analysts have also commented on the stock. BMO Capital Markets restated an outperform rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in […] ....
Avitas Wealth Management LLC purchased a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the fourth quarter, Holdings Channel reports. The firm purchased 1,065 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. A number of other institutional investors and hedge funds also recently made changes to their positions […] ....
Avitas Wealth Management LLC acquired a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 1,065 shares of the biopharmaceutical company’s stock, valued at approximately $204,000. A number of […] ....